ArticleIranian journal of pathology2026
Association of Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) With Molecular Subtypes of Breast Cancer.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Breast cancer (BC) is the most common cancer and a leading cause of cancer-related deaths among Indian women. Inflammation and the tumor microenvironment have a significant influence on cancer development, progression, immune surveillance, and response to therapy. The neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) are simple, measurable markers of subclinical inflammation. This study aimed to evaluate the association of NLR and PLR with the molecular subtypes and clinicopathological parameters of BC. Methods: A hospital-based study was conducted on 228 BC patients. Cases were classified into four molecular subtypes, which were further divided into Group A with a good prognosis (Luminal A and Luminal B) and Group B with a poor prognosis (HER2-enriched and TNBC). Cutoff values for NLR and PLR were calculated using the ROC curve. Results: The cutoff values for NLR and PLR were 2.64 and 90, respectively. NLR was significantly higher (≥2.64) in TNBC (70.6%) and lower (<2.64) in Luminal A (79.2%). Elevated NLR and PLR were associated with clinical T stage (P=0.005 and P=0.028), high PI (P=0.006 and P=0.029), and advanced stage (P=0.002 and P=0.026). A high PLR (≥90) was observed in 60.3% of advanced BC cases, compared to 39.7% of early BC cases. NLR and PLR were negatively correlated with ER and PR (P<0.05). Conclusion: A significant correlation was observed between high NLR and PLR and adverse prognostic clinico-pathological factors in breast cancer. NLR and PLR could serve as valuable, cost-effective markers for prognosis and prediction in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.